Log In
Print this Print this


Also known as: L-FMAU

  Manage Alerts
Collapse Summary General Information
Company Bukwang Pharmaceutical Co. Ltd.
DescriptionNucleoside analog with unnatural L-configuration targeting viral DNA polymerase
Molecular Target Viral DNA polymerase
Mechanism of ActionViral polymerase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat chronic HBV infection; Treat chronic hepatitis B virus (HBV) infection in non-cirrhotic, treatment-naïve, B e-antigen negative patients; Treat hepatitis B virus (HBV) infection; Treat HIV/hepatitis B virus (HBV) co-infection
Regulatory Designation
PartnerEisai Co. Ltd.;
Gilead Sciences Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today